World Muscle Society “25 Challenge” to support Muscular Dystrophy Canada
Many neuromuscular specialists and members of multidisciplinary neuromuscular teams in Canada are part of the World Muscle Society (WMS). WMS provides a multidisciplinary scientific forum to advance and disseminate knowledge in the neuromuscular field for the benefit of patients; stimulates, encourages, and helps to develop programs for professionals working in the neuromuscular field; and promotes the achievement of standards in clinical practice.
This year, the global WMS 2020 meeting was scheduled to take place in beautiful Nova Scotia, Canada and was meant to mark WMS’s 25th anniversary year. But due to COVID-19, the meeting was re-envisioned as a first-ever virtual congress.
Because people living with neuromuscular conditions have been hit particularly hard by the COVID-19 pandemic, WMS has asked all WMS 2020 Congress attendees to get involved by taking on their very own WMS “25 Challenge” to raise money and awareness for relevant charities across the world.
Muscular Dystrophy Canada (MDC), a funder and partner of NMD4C, has been selected as the neuromuscular organization of choice for Canada. This call for support is timely: Due to the COVID-19 pandemic, MDC has seen an increased demand for mental and emotional well-being supports, evidence-based information, essential equipment and advocacy for equity-focused policies. But while there has been an increased demand for their programs and services, the pandemic has significantly affected their available funding. Since the pandemic, MDC has experienced a 60% decrease in revenue. All of their in-person fundraising events have been cancelled and this has been challenging as their organization relies on their supporters and donors to fuel their mission. There has been a 40% cut to funding for the equipment program and a 75% cut to the budget for the Annual Research Grant Competition. In the past year they funded over $1.6 million of research grants and leveraged additional funding for a total of approximately $3.5 million towards team grants and supporting infrastructure. They funded over $1 million in essential equipment and technology supports for people living with neuromuscular disorders, but today they have over 100 individuals on the wait list to receive such life-changing equipment.Let’s not slow down the incredible progress that has been made.
Let’s keep the momentum going – if you are attending the WMS 2020 meeting, participate in the WMS “25 Challenge” and help raise money for MDC.
Click here to get started.
Thank you in advance for your support and for positively impacting the lives of Canadians affected by neuromuscular disorders!
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.